Boston Scientific: Attempting The 2027 Reset
π Analyst Tom Werner retains a buy rating on Boston Scientific (BSX) with a $66 price target.
π The company has slashed guidance and acknowledged competitive pressures in WATCHMAN and electrophysiology segments.
π° Current valuation is assessed as attractive at 13.7x forward earnings.
π― Analyst expects achievable 2024 EPS at the high end of guidance, specifically $3.32.
π Potential for 2025 EPS growth ranges from $3.69 to $4.00 if operational improvements materialize.
β οΈ Further upside is contingent on management halting guidance cuts and delivering execution consistency.
π Recent results were not terrible but show clear signs of deterioration in specific segments.
Bullish Signals
- Analyst maintains a buy rating with a $66 price target, implying substantial upside if negative revisions stabilize.
- Valuation is currently attractive at 13.7x forward earnings, providing a margin of safety for investors.
- 2024 EPS is expected to be achievable at the high end of guidance ($3.32), indicating operational resilience.
- There is potential for significant 2025 EPS growth between $3.69 and $4.00 if management executes operational improvements.
Risk Factors
- The company has recently cut its earnings guidance, signaling a reset of expectations by the market.
- Competitive pressures are explicitly identified as a challenge in the WATCHMAN and electrophysiology segments.
- Clear signs of deterioration are present within specific business units despite recent results not being terrible.
- Future stock upside is contingent on management successfully halting guidance cuts, indicating current trajectory risks.
Full Analysis
Analyst Tom Werner maintains a buy rating on Boston Scientific (BSX) with a $66 price target, suggesting significant upside potential if negative earnings revisions stabilize. The article highlights that the company has reset market expectations by slashing guidance and openly acknowledging competitive pressures within its WATCHMAN and electrophysiology segments.
Valuation metrics appear attractive at 13.7x forward earnings, though further stock appreciation is contingent on management halting guidance cuts and demonstrating consistent execution. The analyst expects achievable 2024 EPS near the high end of the previous guidance range at $3.32.
Looking ahead to 2025, there is potential for EPS growth between $3.69 and $4.00 if operational improvements materialize as planned. While recent results were not terrible, clear signs of deterioration are noted in specific business units, requiring management to address these challenges to unlock the full value implied by the current valuation.